Femasys (FEMY) versus Its Competitors Financial Comparison

Femasys (NASDAQ:FEMYGet Rating) is one of 213 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Femasys to related businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.


This table compares Femasys and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Femasys -733.65% -31.42% -28.81%
Femasys Competitors -748.46% -65.03% -19.49%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Femasys and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Femasys 0 0 3 0 3.00
Femasys Competitors 1279 4595 7992 221 2.51

Femasys currently has a consensus target price of $11.48, indicating a potential upside of 575.49%. As a group, “Surgical & medical instruments” companies have a potential upside of 56.96%. Given Femasys’ stronger consensus rating and higher probable upside, research analysts plainly believe Femasys is more favorable than its competitors.

Institutional and Insider Ownership

4.5% of Femasys shares are held by institutional investors. Comparatively, 50.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 14.3% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Femasys and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Femasys $1.18 million -$7.54 million -1.65
Femasys Competitors $1.15 billion $84.54 million -506.83

Femasys’ competitors have higher revenue and earnings than Femasys. Femasys is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

About Femasys (Get Rating)

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.